2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…2019 American Transplant Congress
Risk Stratification of Cytomegalovirus Seropositive Kidney Transplant Recipients for CMV Infection
1Yale University, New Haven, CT, 2University of Pennsylvania, Philadelphia, PA
*Purpose: Current consensus guidelines for CMV prevention recommend valganciclovir (VGCV) prophylaxis for 3 months after transplantation for CMV R+ kidney transplant recipients (KTR). This standard…2019 American Transplant Congress
Successful Use of Hizentra to Address BK Viremia in Pediatric Transplant Population
Pediatric Nephrology, Saint Louis University, Saint Louis, MO
*Purpose: BK viremia is an important problem in the pediatric renal transplant population leading to increased risk for viral associated nephropathy in the transplant. Early…2019 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
1Surgery, Duke University, Durham, NC, 2University of Massachusetts, Worcester, MA
*Purpose: Porcine islet xenotransplantation has progressed significantly in non-human primate (NHP) studies. However, all successful NHP studies have relied upon immunosuppressive regimens that utilize drugs…2019 American Transplant Congress
Discard Patterns in Donors with Non Alcoholic Fatty Liver Disease
*Purpose: Obesity and nonalcoholic fatty liver disease (NAFLD) are major health issues affecting 20-50% of the US adult population and are increasingly prevalent in potential…2019 American Transplant Congress
Association of Tacrolimus-Level Variance with De Novo DSA within the First 2 Years after Renal Transplantation
*Purpose: Patients that receive an HLA-mismatched kidney transplant (KT) have an increased likelihood to develop de novo DSA (dnDSA). Ideally, immunosuppression is properly adjusted and…2019 American Transplant Congress
Prophylactic Use of Eculizumab in Patients at High Risk of Post-Transplant aHUS Recurrence Improves Graft Outcomes
On behalf of the French aHUS Group, France, France
*Purpose: Eculizumab has revolutionized the management of atypical Hemolytic Uremic Syndrome (aHUS). In 2012, the French aHUS Study Group issued recommendations to advocate the prophylactic…2019 American Transplant Congress
Impact of Early Borderline Histological Changes on Subsequent Events in Renal Transplant Recipients
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: The significance of borderline changes suspicious for rejection noted on early renal allograft biopsies on subsequent events in renal transplant recipients is unclear.*Methods: Between…2019 American Transplant Congress
Center-Level Variation in HLA-Incompatible Living Donor Kidney Transplantation Outcomes
1Johns Hopkins University, Baltimore, MD, 2University of Alabama School of Medicine, Birmingham, AL
*Purpose: Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these variations, as well as other practice variations, on…2019 American Transplant Congress
Vaccine Response as a Predictor of Kidney Transplant Rejection and Serious Infection
Department of Nephrology, Monash Health, Clayton, Australia
*Purpose: Vaccination generates immune memory, including antibodies against harmful pathogens. Transplant immunosuppression prevents similar processes occurring against alloantigens. Transplant recipients have significantly reduced seroresponses to…
- « Previous Page
- 1
- …
- 174
- 175
- 176
- 177
- 178
- …
- 214
- Next Page »